Accéder au contenu
Merck
Toutes les photos(1)

Documents

P0018

Sigma-Aldrich

Pomalidomide

≥98% (HPLC), powder, HbF inducer

Synonyme(s) :

1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide, 4-Amino-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, Actimid, CC-4047, IMiD 3

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C13H11N3O4
Numéro CAS:
19171-19-8
Poids moléculaire :
273.24
Numéro MDL:
MFCD12756407
Code UNSPSC :
12352200
ID de substance PubChem :
329819974
Nomenclature NACRES :
NA.77

product name

Pomalidomide, ≥98% (HPLC)

ligand

pomalidomide

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Pertinence de la réaction

reagent type: ligand

Couleur

yellow

Solubilité

DMSO: ≥14 mg/mL

Température de stockage

2-8°C

Chaîne SMILES 

Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12

InChI

1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)

Clé InChI

UVSMNLNDYGZFPF-UHFFFAOYSA-N

Informations sur le gène

human ... CRBN(51185) , CUL4A(8451) , DDB1(1642) , RBX1(9978)

Catégories apparentées

Application

Pomalidomide has been used:
  • to treat BV173 cells to study the role of proteolysis targeting chimera (PROTAC) compound, JQ1-CRBN, in inducing specific class-I major histocompatibility complex (MHC-I) peptides
  • for apoptosis studies and intracellular calcium analysis
  • as a fetal hemoglobin (HbF) agent to study the additive effect with UNC0638 on the levels of fetal hemoglobin expression in β-thalassemia/ variant hemoglobin E (HbE) erythroid progenitor cells

Actions biochimiques/physiologiques

Pomalidomide is an effective fetal hemoglobin (HbF) inducer that downregulates the key &#947-globin repressors, SRY-box transcription factor 6 (SOX6), and BAF chromatin remodeling complex subunit (BCL11A).
Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog.

Caractéristiques et avantages

This compound is featured on the Cytokine Receptors (Tumor Necrosis Receptor Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

901494

N-Methylated pomalidomide, ≥98%

901495

Pomalidomide-PEG3-NH2 hydrochloride, ≥95%

901496

Pomalidomide-C6-CO2H, ≥98%

901500

Pomalidomide-C3-CO2H, ≥95%

901504

Pomalidomide-PEG3-CO2H, ≥95%

901516

Pomalidomide-PEG1-NH2 hydrochloride, ≥95%

901513

Pomalidomide-PEG2-NH2 hydrochloride, ≥95%

901523

Pomalidomide-PEG1-Alkyne, ≥98%

901531

Pomalidomide-PEG3-Alkyne, ≥95%

901529

Pomalidomide-PEG2-Alkyne, ≥95%

901527

Pomalidomide-PEG1-CO2H, ≥95%

901526

Pomalidomide-PEG2-CO2H, 95%

901525

Pomalidomide-C9-CO2H, ≥95%

901558

Lenalidomide, ≥95%

901835

Pomalidomide-PEG6-Alkyne

901834

Pomalidomide-PEG5-Alkyne, ≥95%

901833

Pomalidomide-PEG4-Alkyne

901830

Pomalidomide-PEG4-NH2 hydrochloride, ≥95%

901829

Pomalidomide-PEG6-CO2H

901828

Pomalidomide-PEG5-CO2H, ≥95%

901824

Pomalidomide-PEG4-CO2H

901860

(S,R,S)-AHPC-PEG6-NH2 hydrochloride, ≥95%

903434

Pomalidomide-PEG6-butyl azide, ≥95%

903442

Pomalidomide-PEG6-butyl iodide, ≥95%

903833

Pomalidomide-PEG2-azide

903825

Pomalidomide-PEG1-azide

903957

(S,R,S)-AHPC-PEG1-azide

904651

(S,R,S)-AHPC-PEG3-azide, ≥95%

904724

Pomalidomide-PEG2-butyl iodide, ≥95%

904708

Pomalidomide-C6-PEG3-butyl iodide, ≥95%

904678

Pomalidomide-PEG3-azide

904686

Pomalidomide-C6-PEG3-butyl azide, ≥95%

904813

(S,R,S)-AHPC-PEG2-azide

904821

(S,R,S)-AHPC-C6-PEG3-butyl azide, ≥95%

904880

Pomalidomide-C6-PEG1-C3-PEG1-butyl azide, ≥95%

904872

Pomalidomide-PEG2-butyl azide, ≥95%

904864

(S,R,S)-AHPC-PEG6-butyl azide, ≥95%

905224

Pomalidomide-PEG6-butyl amine hydrochloride, ≥95%

913979

Biotin-Thalidomide, ≥95%

919381

CCW16, ≥95%

924202

5-Amino-Thalidomide, ≥95%

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H360D

Classification des risques

Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Themistoklis M Tsarouchas et al.
Nature communications, 9(1), 4670-4670 (2018-11-09)
Spinal cord injury leads to a massive response of innate immune cells in non-regenerating mammals, but also in successfully regenerating zebrafish. However, the role of the immune response in successful regeneration is poorly defined. Here we show that inhibiting inflammation
Manh-Cuong Vo et al.
Frontiers in immunology, 9, 1798-1798 (2018-08-21)
We have previously shown that immunization with tumor antigen-loaded dendritic cells (DCs) and the immunomodulating drug, lenalidomide, synergistically potentiates the enhancing antitumor immunity in a myeloma mouse model. In this study, we investigated the immunogenicity of DCs combined with pomalidomide
Yan-Rou Tsai et al.
International journal of molecular sciences, 19(10) (2018-10-24)
Due to its high oxygen demand and abundance of peroxidation-susceptible lipid cells, the brain is particularly vulnerable to oxidative stress. Induced by a redox state imbalance involving either excessive generation of reactive oxygen species (ROS) or dysfunction of the antioxidant
Emma C Fink et al.
Blood, 132(14), 1535-1544 (2018-08-02)
Thalidomide and its derivatives, lenalidomide and pomalidomide, are clinically effective treatments for multiple myeloma and myelodysplastic syndrome with del(5q). These molecules lack activity in murine models, limiting investigation of their therapeutic activity or toxicity in vivo. Here, we report the
Suzanne Lentzsch et al.
Cancer research, 62(8), 2300-2305 (2002-04-17)
Thalidomide has recently been shown to be useful in the treatment of multiple myeloma and may also be useful in the treatment of other hematological malignancies. We have identified a new derivative of thalidomide, S-3-[3-amino-phthalimido]-glutarimide (S-3APG) with dual activity against
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique